Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0P2KG
|
|||
| Former ID |
DCL000404
|
|||
| Drug Name |
GSK1144814
|
|||
| Indication | Alcohol dependence [ICD-11: 6C40.2; ICD-10: F10.2; ICD-9: 303] | Phase 1 | [1] | |
| Schizophrenia [ICD-11: 6A20] | Phase 1 | [2] | ||
| Company |
GSK
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Neuromedin-K receptor (TACR3) | Target Info | Modulator | [3] |
| Substance-P receptor (TACR1) | Target Info | Modulator | [3] | |
| KEGG Pathway | Calcium signaling pathway | |||
| Neuroactive ligand-receptor interaction | ||||
| Measles | ||||
| Panther Pathway | CCKR signaling map ST | |||
| Reactome | G alpha (q) signalling events | |||
| WikiPathways | Gastrin-CREB signalling pathway via PKC and MAPK | |||
| Peptide GPCRs | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| SIDS Susceptibility Pathways | ||||
| Spinal Cord Injury | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01181908) Alcohol Interaction Study. U.S. National Institutes of Health. | |||
| REF 2 | ClinicalTrials.gov (NCT01090440) Pharmacokinetics, Effect of Food, Safety and Tolerability of a New Tablet Formulation of GSK1144814 in Healthy Subjects (MNK112891) in GlaxoSmithKline. | |||
| REF 3 | Pharmacokinetics and central nervous system effects of the novel dual NK1 /NK3 receptor antagonist GSK1144814 in alcohol-intoxicated volunteers.Br J Clin Pharmacol.2013 May;75(5):1328-39. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.